A new COVID-19 variant, designated NB.1.8.1 and nicknamed “Nimbus,” is drawing global attention due to its heightened transmissibility and severe sore throat symptoms, often described as “razor throat.” Health experts are closely monitoring its spread, though they emphasize that widespread immunity from prior infections and vaccinations may mitigate severe outbreaks.
What Makes Nimbus Different?
Professor Shabir Madhi, a leading vaccinologist at Wits Medical School, explained that Nimbus has multiple mutations that enhance its ability to bind to human cells, making it more contagious than earlier strains. However, he noted that population-level immunity—from past infections and vaccinations—has reduced the risk of large-scale surges.
“Unlike earlier waves, where highly transmissible variants spread rapidly, we now have extensive immunity that helps control transmission,” Madhi said.
Symptoms and Risks
Nimbus shares symptoms with other respiratory illnesses, such as influenza, including:
-
Severe sore throat (“razor throat”)
-
Congestion
-
Coughing
Madhi cautioned that high-risk individuals—such as the elderly and those with underlying conditions—should remain vigilant, as vaccines are currently unavailable in South Africa.
Vaccine Shortage Concerns
Despite vaccines being accessible in the U.S. and Europe, pharmaceutical companies have not sought licensing in South Africa, citing low demand. Madhi criticized this as “irresponsible,” given that vulnerable groups still need protection.
How to Stay Protected
With no current COVID-19 vaccines in the country, Madhi advised:
-
Avoid close contact with symptomatic individuals.
-
Wear masks in poorly ventilated spaces.
-
Get the flu vaccine, as influenza is currently dominant in South Africa.
For travelers visiting countries where Nimbus is spreading, he recommended similar precautions and checking for vaccine availability abroad.
No Need for Panic
While Nimbus is highly transmissible, Madhi stressed that South Africa’s surveillance systems remain effective in tracking variants. He discouraged excessive testing unless necessary, given the limited treatment options and high cost of antivirals like Paxlovid (~R15,000 per course).
Looking Ahead
As the world adjusts to COVID-19’s persistence, experts urge a balanced approach—caution without alarm—while advocating for better vaccine access for high-risk populations.
For now, South Africans are encouraged to prioritize hygiene, mask-wearing in crowded spaces, and staying informed as health officials monitor Nimbus’s impact.
